News Sentiment

TXG sentiment intelligence

10X Genomics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 61 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Health Information Services Read-through group
Latest close 42.73 Week of 10 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

79/100 classification confidence.

Company focus 61

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

+9.5% over one week, +48.2% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

10x Genomics to Report Second Quarter 2026 Financial Results on August 6, 2026

Market Reaction

Price moving ahead of tone

60/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 79/100 classification
One-week reaction 9.5% Price confirming higher
Trend fit Trend active 48.2% over four weeks
Fair value 73.9% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 12
Neutral 41
Negative 8

Relevance

Why the article matched

Direct first
Direct company coverage 61
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
TradingView 12
Stock Titan 11
Market source 9
simplywall.st 7
PR Newswire 3
Investing.com 3
StockStory 2
Investing.com Nigeria 2

Event Lens

What the news is about

Classified themes
Market update 34
Earnings 19
Analyst action 3
Balance sheet 3
Deals and strategy 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 61
StocksToTrade Direct company coverage

TXG Stock Climbs As Wall Street Hikes Price Targets

10x Genomics Inc. (TXG) stock has surged over 12% following positive analyst coverage and strategic company developments. Barclays and Citi both raised their price targets for TXG, citing improving sentiment in life science tools and the potential for earnings growth. Key drivers

Tone
Positive 76/100
Event
Earnings
Published
09 Jul 2026 16:58
Source
StocksToTrade
TradingView Direct company coverage

Price to sales forward of 10x Genomics Inc Class A – SWB:1KJ

This article provides the forward price-to-sales ratio for 10x Genomics Inc Class A (SWB:1KJ) listed on the Stuttgart Stock Exchange. It indicates that the market is currently closed with no trades recorded. The content emphasizes financial data and market specifics for this biot

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 20:40
Source
TradingView
TradingView Direct company coverage

ETFs Investing in 10x Genomics Inc Class A Stocks

This article lists various Exchange Traded Funds (ETFs) that hold 10x Genomics Inc Class A stocks. It provides detailed financial information for each ETF, including market value, weight of the stock in the fund, issuer, management style, expense ratio, assets under management (A

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 10:40
Source
TradingView
TradingView Direct company coverage

1KJ Forecast — Price Target — Prediction for 2027

This article provides a forecast and price target for 10x Genomics Inc Class A (1KJ) stock, based on analyst opinions. It includes details on price estimates, historical highs and lows, upcoming earnings reports, and financial metrics such as EPS, revenue, net income, and EBITDA.

Tone
Positive 63/100
Event
Earnings
Published
05 Jul 2026 09:44
Source
TradingView
TradingView Direct company coverage

10x Genomics Inc Class A Actuals & Estimates (FWB:1KJ)

This article provides an overview of 10x Genomics Inc Class A (FWB:1KJ) stock, including financial actuals and estimates, analyst forecasts, and company financial details. It covers stock price history, earnings, revenue, net income, lack of dividends, employee count, and EBITDA.

Tone
Neutral 50/100
Event
Earnings
Published
28 Jun 2026 09:40
Source
TradingView
TradingView Direct company coverage

10x Genomics Inc Class A Actuals & Estimates (DUS:1KJ)

This article provides financial actuals and estimates for 10x Genomics Inc Class A (1KJ) on the Dusseldorf Stock Exchange. It includes analyst opinions on future price targets, historical stock performance, earnings reports, revenue, net income, and employee information. The comp

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 14:09
Source
TradingView
TradingView Direct company coverage

10x Genomics Inc Class A Actuals & Estimates (MUN:1KJ)

This article provides financial actuals and estimates for 10x Genomics Inc Class A (MUN:1KJ), including income statement, balance sheet, and cash flow data. It covers analyst forecasts, historical price performance, upcoming earnings dates, recent earnings per share and revenue f

Tone
Positive 62/100
Event
Earnings
Published
26 Jun 2026 11:39
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of 10x Genomics Inc Class A – LSE:0A88

This article provides financial information for 10x Genomics Inc Class A (LSE:0A88), focusing on its enterprise value to revenue forward. It appears to be a stub or a section from a larger financial data platform, showcasing the company's financial metrics and data sources.

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 11:39
Source
TradingView
TradingView Direct company coverage

10x Genomics Inc Class A Actuals & Estimates (NASDAQ:TXG)

This article provides current and historical financial data and analyst estimates for 10x Genomics, Inc. (NASDAQ:TXG). It covers stock price performance, forecasts, market capitalization, earnings, revenue, and other key financial metrics. The company's next earnings report is an

Tone
Positive 75/100
Event
Earnings
Published
26 Jun 2026 09:41
Source
TradingView
TradingView Direct company coverage

Price to sales forward of 10x Genomics Inc Class A – LSE:0A88

This article provides the "Price to sales forward" metric for 10x Genomics Inc Class A (LSE:0A88). It is a standalone financiero data point without additional analysis or context within the provided content. The relevant financial information is presented as "Period Value Change

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 23:11
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of 10x Genomics Inc Class A – LSE:0A88

This page from TradingView displays financial information for 10x Genomics Inc Class A (LSE:0A88), specifically focusing on its forward price-to-earnings ratio. The content indicates that while the company's stock is listed on the London Stock Exchange, the market was closed at t

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 08:11
Source
TradingView
Investing.com Nigeria Direct company coverage

10x genomics CEO Serge Saxonov sells $1.03m in stock By Investing.com

Serge Saxonov, CEO of 10x Genomics, sold 29,900 shares of company stock for over $1 million on June 22, 2026, under a pre-arranged trading plan. This sale occurred while TXG stock was trading near its 52-week high after a significant gain. The company's stock is currently conside

Tone
Negative 39/100
Event
Market update
Published
25 Jun 2026 04:11
Source
Investing.com Nigeria
Investing.com Direct company coverage

10x genomics CEO Serge Saxonov sells $1.03m in stock

Serge Saxonov, CEO of 10x Genomics, Inc. (NASDAQ:TXG), sold 29,900 shares of Class A Common Stock worth approximately $1.03 million on June 22, 2026, under a pre-arranged trading plan. This sale occurred while TXG stock traded near its 52-week high, and Mr. Saxonov still holds si

Tone
Negative 39/100
Event
Market update
Published
25 Jun 2026 03:11
Source
Investing.com
Stock Titan Direct company coverage

10x Genomics (TXG) CEO sells 30,000 shares under 10b5-1 plan

10x Genomics (TXG) CEO Serge Saxonov sold 30,000 shares of Class A common stock on June 22, 2026, under a pre-arranged Rule 10b5-1 trading plan adopted in November 2025. The sales, totaling over $1 million, occurred at weighted average prices between $33 and $36 per share. After

Tone
Neutral 50/100
Event
Market update
Published
24 Jun 2026 20:09
Source
Stock Titan
Investing.com India Direct company coverage

Form 4 10X Genomics Inc For: 24 June By Investing.com

This article reports on the filing of Form 4 by 10X Genomics Inc. for June 24, as published by Investing.com. It is a brief announcement without further details on the content of the Form 4 filing.

Tone
Neutral 50/100
Event
Market update
Published
23 Jun 2026 21:40
Source
Investing.com India
Finviz Direct company coverage

TXG - 10x Genomics Inc Stock Price and Quote

This article provides a detailed stock overview for 10x Genomics Inc (TXG), including its current stock price, financial metrics, analyst ratings, and recent news. It also lists insider transactions, highlighting sales by key executives. The company is involved in life science te

Tone
Neutral 50/100
Event
Analyst action
Published
19 Jun 2026 15:11
Source
Finviz
Stock Titan Direct company coverage

10x Genomics (TXG) director Suliman sells 5,723 shares in Rule 10b5-1 trades

10x Genomics, Inc. director Shehnaaz Suliman sold a total of 5,723 shares of Class A Common Stock in open-market transactions on June 16, 2026. The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 13, 2026, at weighted average prices of $32.5890

Tone
Negative 35/100
Event
Market update
Published
18 Jun 2026 19:39
Source
Stock Titan